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Dyslipidaemia predisposes to atheroscle-
rosis, and where hypertriglyceridaemia is
severe, also to pancreatitis. Although
most cases of dyslipidaemia have a prima-
ry genetic pathogenesis, a significant pro-
portion of patients have a secondary cause
that can be modified (Table I). In many
populations secondary causes, in particu-
lar the insulin resistance (IR) syndrome
(e.g. metabolic syndrome, syndrome X),
play a dominant role in causing dyslipi-
daemia and in the genesis of coronary
artery disease (CAD). Secondary causes
of dyslipidaemia should always be consid-
ered and may be important for several
reasons:
• they uncover other underlying diseases
that require specific treatment
• they may explain why a previously treat-
able dyslipidaemia has become resistant
to treatment
• they may point to an alternative and
possibly a safer treatment.
In most cases of dyslipidaemia, a modifi-
able secondary factor will be found. Even
where the treatment of the contributory
secondary cause results only in a small
change in the lipogram, the aggressive
management of the modifiable secondary
cause is justifiable and cost-effective, as
this may forestall costly increases in lipid-
lowering medication.
The secondary causes may conveniently




• other disorders of metabolism
• drugs
• diseases (non-metabolic).
Pharmacogenetic studies, including those
on the effect of genes on diet and environ-
mental factors, indicate that genes play a
role in determining how lipid profiles
react  to the environment.This also
applies to how a person reacts when
exposed to one of the secondary causes of
dyslipidaemia, and explains why only a
percentage of those exposed to a sec-
ondary cause will develop dyslipidaemia.
This additional genetic influence is often
responsible for some perturbation in the
metabolism of lipoprotein particles, most
often the triglyceride (TG)-rich particles.
Under normal metabolic conditions these
patients may be entirely normal, but when
exposed to one of the secondary causes
this ‘excessive metabolic load’ precipitates
an ever-worsening cycle of impairment in
lipoprotein metabolism.This may result in
extremely high lipid (in particular TG)
levels or a chylomicronaemia syndrome,
which can in turn precipitate an attack of
pancreatitis. It is worth emphasising that
the majority of patients with an extremely
high total cholesterol (TC) level (> 15
mmol/l) very seldom have increased low-
density lipoprotein cholesterol (LDL-C)
levels such as those with familial hyper-
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Secondary dyslipidaemia
Disorders associated with secondary 
dyslipidaemia are some of the commonest causes
of morbidity and mortality in the South African
population. This article outlines the causes and
management of these disorders.
Although most cases of
dyslipidaemia have a pri -
mary genetic pathogene -
sis, a significant propor -
tion of patients have a
secondary cause that
can be modified. 
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cholesterolaemia. Usually these
patients have very high TG levels,
almost invariably precipitated by a
secondary cause of which poorly
controlled diabetes mellitus is the
commonest.
The management of secondary
dyslipidaemia should not focus on
the lipid profile of the patient.The
patient should be treated as a
whole — including all the other co-
existent non-lipid risk factors. After
dealing with the secondary cause, a
risk assessment must be made by
taking all the risk factors into
account.The lipid profile must be
judged and managed by the com-
pany it keeps — a person with an
isolated hypercholesterolaemia and
no other risk factors may not
require pharmacological treatment,
whereas a person with a lower cho-
lesterol level may need aggressive




Secondary causes of dyslipidaemia
tend to produce characteristic
changes that may aid in finding the
cause (Table II).
Diet
One should question the patient
regarding dietary saturated fat and
cholesterol intake, as these can
raise the LDL-C level. Similarly,
the patient should be questioned
about alcohol and carbohydrate
intake, as well as recent weight
gain, as these can increase the plas-
ma TG level.Where the doctor’s
time is at a premium, a referral to
a capable dietician is well worth
while.
One should remember that some
eating disorders such as anorexia
nervosa may present with dyslipi-
daemia, in which case, paradoxical-




The lipogram of patients with well-
controlled type 1 diabetes fre-
quently reflects the lipid profiles of
the general population, i.e. these
patients also inherit the other sets
of genes that determine the lipid
profiles of the general population.
However, where the diabetes is
poorly controlled, additional dys-
lipidaemia may result, usually in
the form of increased TG and low
high-density lipoprotein cholesterol
(HDL-C) levels. While these
changes are generally modest,
occasionally the severely raised TG
level of a chylomicronaemia syn-
drome is observed and pancreatitis
may develop.
Insulin resistance and type 2
diabetes
A large proportion of the popula-
tion has IR as part of the IR syn-
drome (e.g. metabolic syndrome,
syndrome X).There is a strong
correlation between IR and all the
markers of atherosclerosis, and IR
is a strong predictor for the future
development of CAD. It is not sur-
prising that in some populations of
South Africa IR is the commonest
phenotype seen in patients present-
ing with acute coronary syndrome
(ACS).
As IR progresses, the body is able
to compensate by secreting more
insulin to maintain normogly-
caemia. Hyperinsulinaemia may
have adverse effects and many
years may pass before failure of the
Diet






• Poorly controlled type 1 diabetes
• Type 2 diabetes



















• Chronic renal disease
• Systemic lupus erythematosus
• Nephrotic syndrome
Table I. Causes of secondary dyslipidaemia
MAIN TOPIC
C M E J u l y  2 0 0 3   Vo l . 2 1   N o . 7   367
pancreatic beta-cells supervenes.
Only then will glucose levels rise,
with the development of impaired
glucose tolerance and type 2 dia-
betes. Type 2 diabetes may conve-
niently be seen as the end result of
another disease present for a long
time, namely IR. In the ‘pre-dia-
betic’ phase of the IR syndrome
these patients have the same risk
factors as type 2 diabetics, includ-
ing dyslipidaemia, and are equally
prone to develop macrovascular
disease. Indeed, many of these
‘pre-diabetic’ IR patients die of
their macrovascular disease before
ever developing impaired glucose
tolerance and diabetes. By the time
type 2 diabetes is diagnosed, the
damage has already been done and
macrovascular disease and CAD
are established. Remember that
type 2 diabetics without clinical
CAD have as high a probability of
experiencing an adverse cardiac
event as a non-diabetic who
already has clinical CAD.
Accordingly, type 2 diabetic
patients, taking their lipogram into
consideration, should be managed
as for secondary prevention. It is
tragic that these ‘pre-diabetic’ IR
patients, who are so prone to
develop CAD, are more often than
not viewed as being ‘healthy’ and
do not receive the attention and
risk factor modification they
require!
The abnormalities of the lipid pro-
file seen in type 2 diabetics can
resemble those of IR.The dyslipi-
daemia resulting from IR (and type
2 diabetes) is often subtle, with
seemingly minor changes, and it is
therefore not surprising that this
atherogenic lipid phenotype is
often poorly managed.
The dyslipidaemia of this IR is
manifested by the following:
• Raised TG levels. The TG level
is usually only slightly raised (< 3
mmol/l), but at times a chylomi-
cronaemia syndrome with mas-
sively raised TG levels may devel-
op in genetically susceptible indi-
viduals.
• Decreased HDL-C levels. The
HDL-C level is very often at, or
just below, the lower limit of nor-
mal.This usually accompanies
the raised TG level, and the high
TG/low HDL syndrome is often
missed.
• Post-prandial lipaemia. After a
fatty meal the TG level rises
higher and stays raised longer
than normal.The post-prandial
hypertriglyceridaemia affects
cholesterol ester exchange with
LDL, and subsequent modula-
tion of  TG-rich LDL by HDL
yields small LDL species.This
has still not been standardised
for clinical investigative use.
• Small dense LDL particles.
These patients invariably have
‘small dense LDL’ particles, a
family of LDL particles that are
cholesterol-enriched, very prone
to oxidisation and accordingly
extremely atherogenic.
• Hyper-ApoB. Because of the
small dense LDL particles, the
TG excess Severe TG
High mild to excess:
Secondary cholesterol moderate chylomicronaemia
cause (high LDL-C) (high VLDL) Low HDL-C syndrome
Diet Saturated fats, Weight gain, Low-fat diet Alcohol and fat with
caloric excess, alcohol genetic lipid
anorexia disorder
Drugs Diuretics, Retinoids, Anabolic Glucocorticoids,
glucocorticoids, beta-blockers, steroids, oestrogen,
cyclosporin oestrogens, progestins, genetic lipid
glucocorticoids beta-blockers, disorder
cigarettes
Disorders of Diabetes poorly Type 2 diabetes, Type 2 Diabetes poorly
metabolism controlled, obesity, diabetes, controlled,
hypothyroidism, pregnancy obesity hypothyroidism with
pregnancy genetic lipid disorder
Diseases Nephrotic Chronic renal Chronic renal SLE (rare)
syndrome, failure with/ failure with/
biliary without dialysis, without dialysis
obstruction nephrotic
syndrome
LDL-C = low-density lipoprotein cholesterol; TG = triglyceride; VLDL = very low-density lipoprotein; HDL-C = high-density lipoprotein cholesterol;
SLE = systemic lupus er ythematosus.
Table II. Lipid profile of secondary causes of dyslipidaemia
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number of LDL particles per
unit volume is increased. Bearing
in mind that LDL particles con-
tain only one ApoB molecule per
lipoprotein particle, IR patients
may manifest with increased
ApoB levels or hyper-ApoB.The
ApoB/LDL-C ratio may be
increased, which is a reasonably
good marker for IR but is not yet
accepted for general use.
Similarly, the measurement of
LDL size is difficult and not
cost-effective.
• IR patients inherit a set of genes
determining their IR and also
their characteristic lipid profile.
However, as in type 1 diabetes,
these patients also inherit a total-
ly different cluster of genes that
determine the lipid profiles in the
rest of the population. These
genes may simultaneously but
independently raise the LDL-C
level, which must be managed in
its own right.
The IR syndrome is accompanied
by the following other components
of a cardiovascular risk factor clus-
ter that must be managed as well:
• Hypertension.
• Central obesity. This is part of
the disease and not very easy to
get rid of .
• Impaired glucose tolerance or
overt type 2 diabetes.
• Increased fibrinogen.This
decreases with fibrate treatment.
It is uncertain whether it trans-
lates into a reduction of cardio-
vascular mortality.
• Increased plasminogen activator
type 1 (PAI-1).This impaired
endogenous thrombolysis is
almost invariably present. Advice
as to its modification is uncer-
tain.
The treatment of these IR patients
is as follows:
• Lifestyle modification. These
patients eat well because they live
well. Lifestyle modification has
been shown to be extremely cost-
effective and pays tremendous
dividends with regard to reduc-
tions in cardiovascular mortality.
• Dietary advice, incorporating
caloric restriction for weight loss
and low fat intake, can be very
effective but requires proper
motivation of the patient. A sym-
pathetic dietician can be of great
value.
• Lipid-modifying drugs . Statins
predominantly decrease LDL-C
levels and have lesser effects on
TG and HDL-C levels, whereas
fibrates have a major effect on
lowering TG and raising HDL-C
levels but little effect on LDL-C
levels. Despite this it is still
advised that treatment be started
with a statin, as these drugs have
additional non-lipid-lowering
effects on the vessel wall, which
are beneficial.Where TG levels
are markedly raised (> 5 mmol/l)
treatment may be started with a
fibrate or a fibrate may be added
to a statin to improve the TG
level further and raise the HDL-
C level.
Other disorders of metabolism
Hypothyroidism may present via
an increased TC and LDL-C level,





lipid clinics see a selected group of
patients in whom the incidence of
hypothyroidism is high. However,
the incidence of hypothyroidism in
general practice is low enough to
question the cost-effectiveness of
performing routine thyroid func-
tion tests. Certainly, thyroid func-
tion tests should be borne in mind
where the pre-test probability of
hypothyroidism is high.
In pregnanc y lipid levels continue
to rise with each trimester, but this
is most dramatic during the second
trimester. Pregnancy may unmask
an underlying genetic defect that
can give rise to severe hypertriglyc-
eridaemia and pancreatitis. This
can usually be controlled by diet
and the lipid profile usually nor-
malises postpartum.
Obesity is often associated with
abnormal lipograms, but many
severely obese patients do not have
dyslipidaemia. However, patients
with central obesity and increased
hip/waist ratios are prone to dyslip-
idaemia.These patients are part of
the IR syndrome discussed above
and should be treated aggressively.
Drugs
Drugs should always be considered
as contributory to a dyslipidaemia.
Cardiovascular drugs
Thiazide diuretics affect the lipid
profile in a dose-dependent fash-
ion. Low-dose (12.5 mg/day)
hydrochlorothiazide is metabolical-
ly safe. Beta-blockers also affect
the lipid profile of patients, but this
adverse effect is not universal.
These agents have a profound ben-
eficial effect on cardiovascular
mortality and careful consideration
should be given before withholding
these drugs, even in diabetics!
Amiodarone may cause dyslipi-
daemia directly, but also by caus-
ing hypothyroidism.
Endocrine drugs
Anabolic steroids profoundly lower
HDL-C levels soon after use.
Glucocorticoids have a potent
effect on the lipid profile, which is




d y s l i p i d a e m i a .
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gain and glucose intolerance. In
susceptible persons alpha-oestro-
gens can cause dramatic increases
in TG levels. Transdermal adminis-
tration may have less input on plas-
ma lipids.
Other drugs
Retinoids used for acne can have
profound effects on the lipid pro-
file, especially on TG levels. One
should check for dyslipidaemia
before and during treatment. The
lipogram normalises promptly after
discontinuation of treatment.
Cyclosporin can contribute to 
dyslipidaemia observed after trans-
plantation, and may be aggravated
by the associated administration of
steroids and by weight gain.
Importantly, it can also interact
with some statins, the dosage of
which must be adjusted in this sit-
uation.Antiretroviral therapy is
being used increasingly.The pro-
tease inhibitors can cause a sec-
ondary lipodystrophy and dyslipi-
daemia associated with severe
increases in TC and TG levels.
Non-metabolic diseases
Liver disease
Cholestasis can be associated with
severe increases in TC levels, which
are partially comprised of lipopro-
tein-X. Impaired liver function
may be associated with impaired
production of lipoproteins and this
should be considered if treatment
results appear to be too good to be
true.
Renal disease
Chronic renal failure can be linked
to dyslipidaemia and may be
aggravated by dialysis. Raised TC
levels are a common feature of the
nephrotic syndrome.
Only rarely does systemic lupus
erythematosus (SLE) cause dyslipi-
daemia via the production enzyme





The management of secondary
dyslipidaemia should follow the
general principles listed below:
• Discontinue the suspected drug
and substitute with a lipid-neu-
tral drug.
• Treat the underlying disorder.
• Apply the appropriate dietary fat
restriction.
• Lipid-modifying agents. With
severely raised TG levels, fibrates
may be needed as an adjunct to
the above.Where the LDL-C




Secondary and contributory causes
of dyslipidaemia should always be
considered. Patients have much to
gain, both health wise and wealth
wise, from recognition and appro-
priate management of these causes.
IN A NUTSHELL
In many populations secondary
causes play a dominant role in
causing dyslipidaemia and in the
genesis of coronary artery dis-
ease (CAD).  
Genes also play an impor tant role
in secondary dyslipidaemia.
Extremely raised total cholesterol
levels ( > 15 mmol/l) are usually a
manifestation of a severe hyper-
triglyceridaemia.
Poorly controlled diabetes is the
commonest secondary cause of
massively raised triglyceride lev-
els.
Insulin resistance correlates
strongly with the development of
macrovascular disease.
In some populations the insulin
resistance syndrome is the com-
monest phenotype seen in
patients with acute coronary syn -
dromes.
Type 2 diabetes may conveniently
be regarded as the end result of
another disease that has been
present for a long time, namely
insulin resistance.
‘Pre-diabetic’ insulin-resistant
patients should be managed
aggressively to prevent the pro-
gression of macrovascular dis-
ease.
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